Clinical Trials Logo

Clinical Trial Summary

This study will evaluate whether commonly used blood pressure medications called "ACE inhibitors" can lower parathyroid hormone.


Clinical Trial Description

The RAAS-PARC study will evaluate whether angiotensin-converting enzyme inhibitors (ACEi) can lower parathyroid hormone (PTH) in normal controls and in individuals have a diagnosis of primary hyperparathyroidism.

Emerging data has implicated the renin-angiotensin-aldosterone system (RAAS) activity with increased PTH. The principal investigator, and other investigators, have previously shown that inhibiting the RAAS may lower PTH. The current study will focus on:

1. Normal Physiology: Does an ACEi (which lowers angiotensin II and aldosterone) reduce PTH in normal individuals?

2. Pathophysiology: Does an ACEi reduce PTH in individuals with primary hyperparathyroidism?

The results of this study may have important implications for cardiovascular and skeletal health, as both the RAAS and PTH have been implicated as mediators of these conditions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01691781
Study type Interventional
Source Brigham and Women's Hospital
Contact
Status Completed
Phase N/A
Start date October 2012
Completion date December 2016

See also
  Status Clinical Trial Phase
Completed NCT00377312 - 7 Day Continuous Parathyroid Hormone IV Infusion Phase 0
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT04040946 - Trial Comparing 2 Diagnostic Strategies for Preoperative Localization of Parathyroid Adenoma in Primary Hyperparathyroidism:TEMP / CT With Tc99m-sestaMIBI or PET / CT With F18-choline in First Intention Phase 3
Recruiting NCT03053999 - Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Withdrawn NCT02711059 - Insulin Resistance in Primary Hyperparathyroidism N/A
Completed NCT00887666 - Pilot Study: Hypovitaminosis D, Hyperparathyroidism and Hypomagnesemia in Patients With Congestive Heart Failure N/A
Completed NCT00538720 - Effects of Vitamin D Replacement in Patients With Primary Hyperparathyroidism (PHPT) Phase 1
Terminated NCT03044600 - Gene Expression in Hyperparathyroidism
Completed NCT03747029 - Serum Calcium to Phosphorous (Ca/P) Ratio in the Diagnosis of Ca-P Metabolism Disorders: a Multicentre Study
Completed NCT01872429 - Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients N/A
Completed NCT00800358 - Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism N/A
Recruiting NCT00169806 - Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis N/A
Completed NCT03968510 - Swalqol in Primary Hyperparathyroidism
Completed NCT00501215 - Effect of Parathyroidectomy on Sleep N/A
Completed NCT02591160 - Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism N/A
Recruiting NCT05299632 - F-18 PSMA for Localization of Parathyroid Adenoma
Recruiting NCT02986607 - Corticosteroid Rhythms in Hypoparathyroid Patients Early Phase 1
Completed NCT02432599 - Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas Phase 2
Completed NCT02524041 - Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism N/A
Recruiting NCT05667090 - Effects of Multiple Mega-dose of Vitamin D3 Supplementation on Ameliorating Moderate to Severe Chronic Pain in Hemodialysis Patients N/A